Pretreatment of Swiss mice and Sprague-Dawley rats with glutathione (GSH) reduced the acute lethal toxicity of cis-dichlorodiammine platinum (II) (cis-DDP) in a dose-dependent manner. The protection was accompanied by reduction of both body weight loss and by reduction of nephrotoxicity, as measured by a rise in serum blood urea nitrogen (BUN), creatinine levels and by histopathologic changes, which occurred 4 days following cis-DDP treatment. The antitumor effects of cis-DDP on experimental tumor models (P388 and Gross leukemia) were not significantly altered by GSH treatment. It is suggested that the partial protection by GSH from acute toxicity of the antitumor drug is directly related to protection of renal function.
Get full access to this article
View all access options for this article.
References
1.
AllenR.C., GaleG.R., OullaP.M., GaleA.O.: Effect of certain antitumor platinum compounds on kidney estrases. Bioinorg. Chem., 8: 83–89, 1978.
2.
AshtonW.D.: « The Logit Transformation », Griffin, London, 1972.
3.
AullJ.L., RiceA.C., TebbettsL.A.: Platinum complex interaction with sulfhydryl groups of thymidylate synthetase. Biochemistry, 16: 672–677, 1977.
4.
AullJ.L., AllenR.L., BapatA.R., DaronH.N., FriedmanM.E., WilsonJ.R.: Effects of platinum complexes on seven enzymes. Biochim. Biophys. Acta, 571: 352–358, 1979.
5.
BallC.R.: Estimation and identification of thiols in rat spleen after cysteine or glutathione treatment: Relevance to protection against nitrogen mustards. Biochem. Pharmacol., 15: 809–816, 1966.
6.
BennettW.M., PastoreL., HoughtonD.C.: Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat. Rep., 64: 921–924, 1980.
7.
BorschR.F., PleasantsM.E.: Inhibition of cisplatinum nephrotoxicity by diethyldithiocarbamate. Proc. Natl. Acad. Sci. USA, 76: 6611–6614, 1979.
8.
DentinoM., LuftF.C., YumM.N.: Long term effect of c/s-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer, 41: 1274–1281, 1978.
9.
FillipskiT., KohnK.W., PratherR.: Thiourea reverses cross-links and restores biological activity in DNA treated with dichlorodiammineplatinum (II). Science, 204: 181–184, 1979.
10.
FriedmanM.E., MeliusP., TegginsJ.E., McAuliffeC.A.: Interactions of cis and trans-platinum (II) complexes with dehydrogenase enzymes in the presence of different mono- and polynucleotides. Evidence for ternary complex. Bioinorg. Chem., 8: 341–353, 1978.
11.
GeranR.I., GreenbergN.H., McDonaldM.M., SchumacherA.M., AbbottB.J.: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., 3: 1–88, 1972.
12.
HahnR., WendelA., FlohéL.: The fate of extracellular glutathione in the rat. Biochim. Biophys. Acta, 539: 324–337, 1978.
13.
HowellS.B., TaetleR.: Effect of sodium thio-sulfate on cis-dichlorodiammineplatinum (II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat. Rep., 64: 611–616, 1980.
14.
KaufmanG.B., CowanD.O.: Cis and trans-dichlorodiammineplatinum II. In « Inorganic syntheses », KleinbergJ. ed., New York, McGraw-Hill, vol. 7, pp. 239–245, 1963.
15.
LeviT., JacobsC., KaimanS., McTigueM., WeinerM.: Mechanism of cis-platinum nephrotoxicity. I. Effects of sudfhydryl groups in rat kidney. J. Pharmacol. Exp. Ther., 213: 545–550, 1980.
16.
LitterstC.L., TongS., HirokataY., SiddikZ.H.: Alterations in hepatic and renal levels of glutathione and activities of glutathione S-transferrases from rats treated with cis-dichlorodiammineplatinum-II. Cancer Chemother. Pharmacol., 8: 67–71, 1982.
17.
MadiasN.E., HarringtonT.T.: Platinum nephrotoxicity. Am. J. Med., 65: 307–314, 1978.
18.
MeisterA., TateS.S.: Glutathione and related γ-glutamyl compounds: Biosynthesis and utilization. Ann. Rev. Biochem., 45: 559–604, 1976.
19.
RossD.A., GaleG.R.: Reduction of the renal toxicity of c/s-dichlorodiammineplatinum (II) by probenecid. Cancer Treat. Rep., 63: 781–789, 1979.
20.
RozencweigM., Von HoffD.D., AbeleR., MuggiaF.M.: Cisplatin. In: Cancer Chemotherapy, PinedoH.M. ed., Excerpta Medica, Amsterdam, pp. 120–132, 1981.
21.
SlaterT.F., AhmedM., IbrahimS.A.: Studies on the nephrotoxicity of cis-dichlorodiammine-platinum2+ and related substances. J. Clin. Hematol. Oncol., 7: 534–546, 1977.
22.
YoshimuraK., IwauchiY., SugiyamaS., KuwamuraT., OdakaY., SatohT., KitagawaH.: Transport of L-cysteine and reduced glutathione through biological membranes. Res. Comm. Chem. Pathol. Pharmacol., 37: 171–185, 1982.
23.
YuhasJ.M., CuloF.: Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Cancer Treat. Rep., 64: 57–64, 1980.
24.
WardJ., FauvieK.: Nephrotoxicity effects of cis-diamminedichloroplatinum (II) in male F344 rats. Toxicol. Appl. Pharmacol., 38: 535–547, 1976.
25.
ZuninoF., GiulianiF., SaviG., DasdiaT., GambettaR.: Antitumor activity of daunorubicin linked to poly-L-aspartic acid. Int. J. Cancer., 30: 465–470, 1982.
